PREDQ (Predictive Technology Group) Beta: -1.3354 (As of Jun. 25, 2026)


What is Predictive Technology Group Beta?

Predictive Technology Group PREDQ -90.00% Beta is -1.3354 as of Jun. 25, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Predictive Technology Group's Beta is -1.3354.

Predictive Technology Group  (OTCPK:PREDQ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Predictive Technology Group Beta Related Terms

Predictive Technology Group Beta Historical Data

* Premium members only.

The historical data trend for Predictive Technology Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Predictive Technology Group Beta Chart

Predictive Technology Group Annual Data
Trend Aug06 Aug07 Jun16 Jun17 Jun18 Jun19 Jun20
Beta
Get a 7-Day Free Trial -8.19 -12.63 -3.92 1.50 0.36

Predictive Technology Group Quarterly Data
Nov07 Feb08 May08 Jun16 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.36 0.46 -0.15 -1.16

PREDQ vs GLMD, RCAR, CKPT: Beta Comparison

For the Biotechnology subindustry, Predictive Technology Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predictive Technology Group Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Predictive Technology Group's Beta distribution charts can be found below:

* The bar in red indicates where Predictive Technology Group's Beta falls into.


Predictive Technology Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -1.3354 mean?
Predictive Technology Group (PREDQ) has a Beta of -1.3354 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Predictive Technology Group and its competitors.
Is Predictive Technology Group's Beta too high?
Predictive Technology Group's current Beta is -1.3354.
How does Predictive Technology Group's Beta compare to GLMD and RCAR?
Predictive Technology Group's Beta of -1.3354 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Predictive Technology Group and its competitors. Predictive Technology Group's current Beta is -1.3354. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predictive Technology Group stock overvalued right now?
Predictive Technology Group (PREDQ) has a current Beta of -1.3354. The current Beta is -1.3354. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Predictive Technology Group (PREDQ), the current Beta is -1.3354 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Predictive Technology Group Business Description

Address 2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109
Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.